Myocardial Inflammation—Are We There Yet?

被引:51
|
作者
Greulich S. [1 ]
Ferreira V.M. [2 ]
Dall’Armellina E. [2 ]
Mahrholdt H. [1 ]
机构
[1] Division of Cardiology, Robert Bosch Medical Center, Auerbachstrasse 110, Stuttgart
[2] Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, John Radcliffe Hospital, Headley Way, Headington, Oxford
关键词
Cardiovascular magnetic resonance; Edema; Gadolinium; Mapping; Myocardial inflammation; Tissue characterization;
D O I
10.1007/s12410-015-9320-6
中图分类号
学科分类号
摘要
Several exogenous or endogenous factors can lead to inflammatory heart disease. Beside infectious myocarditis, other systemic inflammatory disorders such as sarcoidosis, systemic lupus erythematosus (SLE), systemic sclerosis (SSc), Churg-Strauss syndrome, and rheumatoid arthritis can affect the myocardium. Myocardial inflammation may have a major impact on the outcome of these patients, resulting in sudden cardiac death, severe arrhythmias, or end-stage heart failure. The current gold standard for definite confirmation of inflammatory heart disease is endomyocardial biopsy (EMB), but is invasive and suffers low sensitivity and specificity due to sampling errors. Thus, non-invasive methods for detecting the extent and changes over time of the inflammatory myocardial disease are needed. Cardiac magnetic resonance (CMR) is such a non-invasive method. We will describe and discuss different approaches for CMR assessment of inflammatory myocardial disease including early gadolinium enhancement (EGE), T2-weighted imaging, late gadolinium enhancement (LGE), the newer mapping proton relaxation techniques (T1 pre-contrast, T1 post-contrast, T2 mapping), and the hybrid PET/MRI technique. © 2015, The Author(s).
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Detecting and Targeting Inflammation in Genetic Cardiomyopathies Are We There Yet?
    Pinney, Sean P.
    Mann, Douglas L.
    JACC-BASIC TO TRANSLATIONAL SCIENCE, 2023, 8 (07): : 766 - 768
  • [2] Are we there yet? Are we there yet?
    Conrad, Charles
    Malphurs, Ryan
    MANAGEMENT COMMUNICATION QUARTERLY, 2008, 22 (01) : 123 - 146
  • [3] Targeting Myocardial Energetics in the Failing Heart Are We There Yet?
    Mann, Douglas L.
    CIRCULATION-HEART FAILURE, 2017, 10 (12)
  • [4] Tackling inflammation in atherosclerosis: Are we there yet and what lies beyond?
    Bhattacharya, Purbasha
    Kanagasooriyan, Ragulan
    Subramanian, Manikandan
    CURRENT OPINION IN PHARMACOLOGY, 2022, 66
  • [5] Native Myocardial T1 Mapping, Are We There Yet?
    Hamdy, Ahmed
    Kitagawa, Kakuya
    Ishida, Masaki
    Sakuma, Hajime
    INTERNATIONAL HEART JOURNAL, 2016, 57 (04) : 400 - 407
  • [6] Tissue Doppler imaging for detection of myocardial ischemia: are we there yet?
    Douwe E. Atsma
    The International Journal of Cardiovascular Imaging, 2003, 19 (4) : 323 - 324
  • [7] Tissue Doppler imaging for detection of myocardial ischemia: are we there yet?
    Atsma, DE
    INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING, 2003, 19 (04): : 323 - 324
  • [8] Lowering inflammation through lipid-lowering therapy: are we there yet?
    Agarwal, Nayan
    Golwala, Harsh
    EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES, 2020, 6 (02) : 93 - 94
  • [9] Stem Cells and Organoid Technology in Precision Medicine in Inflammation: Are We There Yet?
    Tran, Florian
    Klein, Christine
    Arlt, Alexander
    Imm, Simon
    Knappe, Evelyn
    Simmons, Alison
    Rosenstiel, Philip
    Seibler, Philip
    FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [10] Mapping Myocardial Salvage Index by Extracellular Volume Fraction Are We There Yet?
    Bulluck, Heerajnarain
    Hausenloy, Derek J.
    CIRCULATION-CARDIOVASCULAR IMAGING, 2017, 10 (07)